Literature DB >> 22310535

Profile of circulating levels of IL-1Ra, CXCL10/IP-10, CCL4/MIP-1β and CCL2/MCP-1 in dengue fever and parvovirosis.

Luzia Maria de-Oliveira-Pinto1, Mariana Gandini, Laís Picinini Freitas, Marilda Mendonça Siqueira, Cíntia Ferreira Marinho, Sérgio Setúbal, Claire Fernandes Kubelka, Oswaldo Gonçalves Cruz, Solange Artimos de Oliveira.   

Abstract

Dengue virus (DENV) and parvovirus B19 (B19V) infections are acute exanthematic febrile illnesses that are not easily differentiated on clinical grounds and affect the paediatric population. Patients with these acute exanthematic diseases were studied. Fever was more frequent in DENV than in B19V-infected patients. Arthritis/arthralgias with DENV infection were shown to be significantly more frequent in adults than in children. The circulating levels of interleukin (IL)-1 receptor antagonist (Ra), CXCL10/inducible protein-10 (IP-10), CCL4/macrophage inflammatory protein-1 beta and CCL2/monocyte chemotactic protein-1 (MCP-1) were determined by multiplex immunoassay in serum samples obtained from B19V (37) and DENV-infected (36) patients and from healthy individuals (7). Forward stepwise logistic regression analysis revealed that circulating CXCL10/IP-10 tends to be associated with DENV infection and that IL-1Ra was significantly associated with DENV infection. Similar analysis showed that circulating CCL2/MCP-1 tends to be associated with B19V infection. In dengue fever, increased circulating IL-1Ra may exert antipyretic actions in an effort to counteract the already increased concentrations of IL-1β, while CXCL10/IP-10 was confirmed as a strong pro-inflammatory marker. Recruitment of monocytes/macrophages and upregulation of the humoral immune response by CCL2/MCP-1 by B19V may be involved in the persistence of the infection. Children with B19V or DENV infections had levels of these cytokines similar to those of adult patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22310535     DOI: 10.1590/s0074-02762012000100007

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  20 in total

1.  Utility of humanized BLT mice for analysis of dengue virus infection and antiviral drug testing.

Authors:  Natalia Frias-Staheli; Marcus Dorner; Svetlana Marukian; Eva Billerbeck; Rachael N Labitt; Charles M Rice; Alexander Ploss
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

2.  Comprehensive Immunoprofiling of Pediatric Zika Reveals Key Role for Monocytes in the Acute Phase and No Effect of Prior Dengue Virus Infection.

Authors:  Daniela Michlmayr; Eun-Young Kim; Adeeb H Rahman; Rohit Raghunathan; Seunghee Kim-Schulze; Yan Che; Selim Kalayci; Zeynep H Gümüş; Guillermina Kuan; Angel Balmaseda; Andrew Kasarskis; Steven M Wolinsky; Mayte Suaréz-Fariñas; Eva Harris
Journal:  Cell Rep       Date:  2020-04-28       Impact factor: 9.423

3.  Dengue Virus M Protein Promotes NLRP3 Inflammasome Activation To Induce Vascular Leakage in Mice.

Authors:  Pan Pan; Qi Zhang; Weiyong Liu; Yingle Liu; Geng Li; Jianguo Wu; Wenbiao Wang; Zizhao Lao; Wei Zhang; Miaomiao Shen; Pin Wan; Feng Xiao; Fang Liu; Wen Zhang; Quiping Tan; Xiaohong Liu; Kailang Wu
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

4.  Loss of Interleukin 1 Receptor Antagonist Enhances Susceptibility to Ebola Virus Infection.

Authors:  Lindsay Hill-Batorski; Peter Halfmann; Andrea Marzi; Tiago J S Lopes; Gabriele Neumann; Heinz Feldmann; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2015-07-23       Impact factor: 5.226

5.  DENV inhibits type I IFN production in infected cells by cleaving human STING.

Authors:  Sebastian Aguirre; Ana M Maestre; Sarah Pagni; Jenish R Patel; Timothy Savage; Delia Gutman; Kevin Maringer; Dabeiba Bernal-Rubio; Reed S Shabman; Viviana Simon; Juan R Rodriguez-Madoz; Lubbertus C F Mulder; Glen N Barber; Ana Fernandez-Sesma
Journal:  PLoS Pathog       Date:  2012-10-04       Impact factor: 6.823

6.  Unravelling the patterns of host immune responses in Plasmodium vivax malaria and dengue co-infection.

Authors:  Vitor R R Mendonça; Bruno B Andrade; Ligia C L Souza; Belisa M L Magalhães; Maria P G Mourão; Marcus V G Lacerda; Manoel Barral-Netto
Journal:  Malar J       Date:  2015-08-14       Impact factor: 2.979

Review 7.  Biomarkers of severe dengue disease - a review.

Authors:  Daisy Vanitha John; Yee-Shin Lin; Guey Chuen Perng
Journal:  J Biomed Sci       Date:  2015-10-14       Impact factor: 8.410

8.  Cytokines and chemokines as biomarkers of community-acquired bacterial infection.

Authors:  Michal Holub; David A Lawrence; Nancy Andersen; Alžběta Davidová; Ondřej Beran; Vilma Marešová; Pavel Chalupa
Journal:  Mediators Inflamm       Date:  2013-04-16       Impact factor: 4.711

Review 9.  Antiviral macrophage responses in flavivirus encephalitis.

Authors:  Thomas Myles Ashhurst; Caryn van Vreden; Luis Munoz-Erazo; Paula Niewold; Kanami Watabe; Rachael L Terry; Celine Deffrasnes; Daniel R Getts; Nicholas Jonathan Cole King
Journal:  Indian J Med Res       Date:  2013-11       Impact factor: 2.375

10.  Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.

Authors:  Anke Harenberg; Aymeric de Montfort; Frédérique Jantet-Blaudez; Matthew Bonaparte; Florence Boudet; Melanie Saville; Nicholas Jackson; Bruno Guy
Journal:  PLoS Negl Trop Dis       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.